RSR13 (efaproxiral/Efaproxyn) : Allos Therapeutics : Radiation sensitizer

Phase III Trial Suggests that some NSCLC Patients with Brain Metastases May Benefit from RSR13 (Allos Therapeutics)
Press release announcing results from a Phase III trial of the radiation sensitizer RSR13 (efaproxiral) that demonstrated a survival benefit in a group of patients with brain metastases originating from NSCLC. Provides details of the trial, which was presented at the 2004 annual ASCO meeting. [6/04]

Adjunctive RSR13 Improves Outcomes in Locally Advanced NSCLC (Doctor's Guide)
Reports on the results of a trial involving 47 patients with locally advanced, inoperable lung cancer that showed adjunctive use of a radiation-sensitizing agent (RSR13) led to an unexpectedly high response rate to induction chemotherapy and radiation therapy. [05/01]

RSR13 (efaproxiral/Efaproxyn) - Recent MEDLINE Abstracts (PubMed)